Fosamax and Osteonecrosis of the Jaw: Medical Literature on Causation and Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Occupational Exposure

The legacy of general health and science information dissemination has long served as a foundation for public awareness, emphasizing broad educational outreach and the communication of established medical knowledge. Within this tradition, the focus has typically been on lifestyle factors, preventive care, and the management of common conditions, often drawing from population-level data to inform guidance. This heritage provides a valuable framework for understanding how health risks are identified and communicated across diverse contexts. Transitioning from this broad perspective, a more targeted concern emerges when considering specific pharmaceutical exposures in occupational settings. In mass production environments, workers may encounter materials or compounds that, while beneficial in therapeutic contexts, pose unique risks under chronic or high-level exposure conditions. The case of bisphosphonate medications, such as Fosamax, illustrates this pivot: originally studied within general health frameworks for bone density management, subsequent observations have linked such agents to rare but serious adverse events, including osteonecrosis of the jaw. This shifts the inquiry from a general health audience to a focused occupational health question, where the potential for exposure—whether through manufacturing processes, handling, or environmental contamination—requires careful assessment. The transition thus moves from broad health literacy to a specific, workplace-centered risk evaluation, maintaining a neutral stance while highlighting the need for targeted surveillance and protective measures in industrial settings.

Fosamax and Osteonecrosis of the Jaw: An Overview

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed necrotic bone in the maxillofacial region, often presenting with delayed healing after dental procedures. Clinical presentation may include pain, swelling, infection, and exposed bone. Diagnosis typically involves clinical examination and imaging, though the condition can occur spontaneously (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). This suggests that the unique biology of the jawbone may contribute to its susceptibility to this adverse effect.

Risk Factors and Duration of Use

The risk of ONJ in patients taking Fosamax is influenced by several factors. Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping, though a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold after 10 years compared with past use, though absolute risks remained low (~0.05% after 5 years) and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702).

Warnings and Causation Considerations

The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under section 5.4, "Osteonecrosis of the Jaw," which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that ONJ is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Additionally, the label for Fosamax Plus D similarly warns of ONJ and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings provide information to healthcare providers and patients about the potential risk. For causation-related considerations, affected patients should be aware that ONJ is a rare but serious adverse effect. The evidence indicates that the risk increases with longer duration of use, and that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between exposure and harm can vary, with symptoms appearing from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The absolute risk remains low, but patients with additional risk factors, such as those undergoing invasive dental procedures or with co-morbid conditions, may be at higher risk. In summary, Fosamax is associated with an increased risk of ONJ, particularly with longer duration of use and in the presence of other risk factors. The prescribing information includes warnings about this adverse effect, and patients should be counseled on the importance of dental care and the potential need for treatment discontinuation before invasive dental procedures. The mechanistic understanding of ONJ in the context of bisphosphonate use continues to evolve, with ongoing research into jawbone-specific responses (https://pubmed.ncbi.nlm.nih.gov/40345077).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

ONJ is a condition involving exposed necrotic bone in the jaw, often after dental procedures. Fosamax and other bisphosphonates have been associated with an increased risk of ONJ, especially with longer use and additional risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, and co-morbid conditions like periodontal disease. The risk increases with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.